BamSEC and AlphaSense Join Forces
Learn More

Harrow Inc Com

NASDAQ: HROW    
Share price (1/3/25): $36.34    
Market cap (1/3/25): $1.294 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.46
from 10-K 5 pages Third Amendment to License and Supply Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Second Amendment to License and Supply Agreement
12/34/56
EX-10.1
from 8-K 53 pages Asset Purchase Agreement by and Among Novartis Technology LLC and Novartis Innovative Therapies AG and Harrow Health, Inc., Harrow Eye, LLC and Harrow Ip, LLC Dated as of December 13, 2022
12/34/56
EX-10.3
from 10-Q 3 pages Mutual Termination of the Agreement: The Parties Agree That, Effective on the Mutual Termination Effective Date, the Agreement Shall Be Deemed Terminated by the Mutual Agreement of the Parties. the Parties Further Agree as Follows
12/34/56
EX-10.1
from 10-Q 42 pages Recitals
12/34/56
EX-10.51
from 10-K 41 pages Asset Purchase Agreement by and Between Novartis Technology LLC and Novartis Ophthalmics AG and Harrow Health, Inc. Dated as of 17 December, 2021
12/34/56
EX-10.50
from 10-K 7 pages Portions of This Exhibit Indicated by Bracketed Asterisks Have Been Omitted Because They Are Not Material and Would Likely Cause Competitive Harm to Harrow Health, Inc. if Publicly Disclosed. December 6, 2021 via Email Imprimis Rx, LLC 12264 El Camino Real Suite 350 San Diego, California 92130 Attn: John Saharek Email: Re: Commercial Alliance Agreement: Expansion of Imprimis Responsibilities Changes to the Agreement
12/34/56
EX-10.4
from 10-Q 27 pages License Agreement by and Between Wakamoto Pharmaceutical Co., Ltd. and Harrow Health, Inc. August 18, 2021 1 License Agreement
12/34/56
EX-10.3
from 10-Q 16 pages Basic Sale and Purchase Agreement
12/34/56
EX-10.1
from 8-K 43 pages Recitals
12/34/56
EX-10.2
from 10-Q 52 pages License and Supply Agreement
12/34/56
EX-10.1
from 8-K 12 pages Securities Purchase Agreement
12/34/56
EX-10.60
from 10-K 4 pages November 12, 2020 via Email Eyepoint Pharmaceuticals, Inc. 480 Pleasant Street Suite B300 Watertown, Massachusetts 02472 Attn: Nancy Lurker Email: Nlurker@eyepointpharma.com Re: Amendment One to the Commercial Alliance Agreement Changes to the Agreement
12/34/56
EX-10.58
from 10-K 11 pages Visionology, Inc. Consulting Agreement
12/34/56
EX-10.57
from 10-K 11 pages Visionology, Inc. Consulting Agreement
12/34/56
EX-10.1
from 10-Q 26 pages Commercial Alliance Agreement
12/34/56
EX-10.66
from 10-K 13 pages Stowe Pharmaceuticals, Inc. Consulting Agreement
12/34/56
EX-10.65
from 10-K 13 pages Stowe Pharmaceuticals, Inc. Consulting Agreement
12/34/56
EX-10.64
from 10-K 13 pages Stowe Pharmaceuticals, Inc. Consulting Agreement
12/34/56
EX-10.4
from 10-Q 23 pages License Agreement
12/34/56